NRKBF yields 1.58% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, NRKBF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NRKBF + JNJ for your $10,000?
NKT A/S develops, manufactures, and markets cables, accessories, and solutions worldwide. It operates through Solutions, Applications, Service & Accessories, and NKT Photonics segments. It offers high voltage cable solutions, including high voltage onshore and offshore AC and DC, city, and dynamic cables; medium voltage and universal cables; and low voltage building wires, flexible cables and conduits, control cables, 1 kV cables, and telecom energy cables. The company also provides high voltage cable accessories, such as GIS/transformer, low pressure oil filled cable system, outdoor terminations, wind power applications, and transition joints; medium voltage cable accessories, which include medium voltage cable joints, cable connectors, voltage terminations, cable branch cabinets, paper-insulated lead sheath cables, and pre-assembled cable links. In addition, it offers onshore cable services comprising of repair preparedness, monitoring solutions, maintenance, spare parts management, resources on call, and cable jointing and termination; offshore cable services consisting of marine resource plan; high voltage testing services; and oil and gas cable competence center services, as well as provides technology consulting services. The company was formerly known as NKT Holding A/S and changed its name to NKT A/S in May 2017. NKT A/S was founded in 1891 and is headquartered in Brøndby, Denmark.
Full NRKBF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.